Related Experiment Video

Updated: May 5, 2026

Detection of Live Escherichia coli O157:H7 Cells by PMA-qPCR
08:16

Detection of Live Escherichia coli O157:H7 Cells by PMA-qPCR

Published on: February 1, 2014

16.6K

First report of KPC-35-producing Klebsiella pneumoniae ST258 isolated in Peru

Arturo Gonzales-Rodriguez1, Juan Carlos Gómez-de-la-Torre2, Luis Alvarado2

  • 1Universidad de Piura, Facultad de Medicina Humana, Lima, Peru.

Revista Argentina De Microbiologia
|January 23, 2025
PubMed

Insights

The emergence of Klebsiella pneumoniae ST258 with new KPC variants, including ceftazidime/avibactam resistance, poses a significant public health threat. This study reports the first cases in Peru, highlighting the urgent need for surveillance and new treatment strategies.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Antimicrobial Resistance

Background:

  • Klebsiella pneumoniae sequence type 258 (ST258) is a major driver of carbapenemase-producing Enterobacteriaceae (KPC) infections globally.
  • Ceftazidime/avibactam (CZA) was introduced in 2015 as a treatment option for KPC infections, but resistance has since emerged.
  • The spread of KPC-producing bacteria, particularly ST258, represents a critical public health challenge.

Purpose of the Study:

  • To report the identification of K. pneumoniae ST258 isolates from a patient in Peru.
  • To characterize the antimicrobial resistance profiles, including resistance to CZA, of these isolates.
  • To highlight the emergence of CZA resistance in K. pneumoniae ST258 in a new geographical region.

Main Methods:

  • Isolation and identification of K. pneumoniae from patient samples.
  • Antimicrobial susceptibility testing, including carbapenems and CZA.
  • Molecular characterization of resistance genes, specifically blaKPC variants.

Main Results:

  • Two consecutive K. pneumoniae ST258 isolates (KP1 and KP2) were identified from a urinary tract infection patient.
  • KP1 harbored blaKPC-2, while KP2 harbored blaKPC-35.
  • KP2 displayed reduced susceptibility to carbapenems and confirmed resistance to CZA.
  • This represents the first report of K. pneumoniae ST258 in Peru.

Conclusions:

  • The findings underscore the increasing global challenge of CZA resistance in K. pneumoniae ST258.
  • The emergence of CZA-resistant K. pneumoniae ST258 in Peru necessitates enhanced surveillance and infection control measures.
  • Continuous monitoring for emerging resistance mechanisms is crucial for effective antimicrobial stewardship.
Keywords:
Drug resistanceKlebsiella pneumoniaePeruPerúResistencia a los antimicrobianos

More Related Videos

Culture Methods to Determine the Limit of Detection and Survival in Transport Media of Campylobacter Jejuni in Human Fecal Specimens08:23

Culture Methods to Determine the Limit of Detection and Survival in Transport Media of Campylobacter Jejuni in Human Fecal Specimens

Published on: March 10, 2020

11.5K
Author Spotlight: Advancing Rapid Detection of Respiratory Pathogens Using Microfluidic Chip06:11

Author Spotlight: Advancing Rapid Detection of Respiratory Pathogens Using Microfluidic Chip

Published on: March 29, 2024

1.5K

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
842